Department of Pharmacology, Hebei Medical University, Shijiazhuang, China; The Key Laboratory of New Drug Pharmacology and Toxicology, Shijiazhuang, China; The Key Laboratory of Neural and Vascular Biology, Ministry of Education, Shijiazhuang, China.
Hebei Institute for Drug Control, Shijiazhuang, China.
Br J Pharmacol. 2017 Dec;174(23):4464-4477. doi: 10.1111/bph.14049. Epub 2017 Nov 7.
Elevated angiotensin II (Ang II) and sympathetic activity contributes to a high risk of ventricular arrhythmias in heart disease. The rapidly activating delayed rectifier K current (I ) carried by the hERG channels plays a critical role in cardiac repolarization, and decreased I is involved in increased cardiac arrhythmogenicity. Stimulation of α -adrenoreceptors or angiotensin II AT receptors is known to inhibit I via PKC. Here, we have identified the PKC isoenzymes mediating the inhibition of I by activation of these two different GPCRs.
The whole-cell patch-clamp technique was used to record I in guinea pig cardiomyocytes and HEK293 cells co-transfected with hERG and α -adrenoreceptor or AT receptor genes.
A broad spectrum PKC inhibitor Gö6983 (not inhibiting PKCε), a selective cPKC inhibitor Gö6976 and a PKCα-specific inhibitor peptide, blocked the inhibition of I by the α -adrenoreceptor agonist A61603. However, these inhibitors did not affect the reduction of I by activation of AT receptors, whereas the PKCε-selective inhibitor peptide did block the effect. The effects of angiotensin II and the PKCε activator peptide were inhibited in mutant hERG channels in which 17 of the 18 PKC phosphorylation sites were deleted, whereas a deletion of the N-terminus of the hERG channels selectively prevented the inhibition elicited by A61603 and the cPKC activator peptide.
Our results indicated that inhibition of I by activation of α -adrenoreceptors or AT receptors were mediated by PKCα and PKCε isoforms respectively, through different molecular mechanisms.
血管紧张素 II(Ang II)和交感神经活性升高会增加心脏病患者发生室性心律失常的风险。由 hERG 通道携带的快速激活延迟整流钾电流(I )在心脏复极中起关键作用,而 I 的减少与心脏致心律失常性增加有关。已知刺激α-肾上腺素能受体或血管紧张素 II AT 受体可通过 PKC 抑制 I 。在这里,我们已经确定了介导这两种不同 GPCR 激活抑制 I 的 PKC 同工酶。
使用全细胞膜片钳技术记录豚鼠心肌细胞和共转染 hERG 和α-肾上腺素能受体或 AT 受体基因的 HEK293 细胞中的 I 。
广谱 PKC 抑制剂 Gö6983(不抑制 PKCε)、选择性 cPKC 抑制剂 Gö6976 和 PKCα 特异性抑制剂肽阻断了α-肾上腺素能受体激动剂 A61603 对 I 的抑制。然而,这些抑制剂对 AT 受体激活引起的 I 减少没有影响,而 PKCε 选择性抑制剂肽则阻断了这种作用。在 18 个 PKC 磷酸化位点中有 17 个缺失的突变 hERG 通道中,血管紧张素 II 和 PKCε 激活肽的作用被抑制,而 hERG 通道的 N 端缺失则选择性地阻止了 A61603 和 cPKC 激活肽引起的抑制作用。
我们的结果表明,α-肾上腺素能受体或 AT 受体的激活抑制 I 分别由 PKCα 和 PKCε 同工酶介导,通过不同的分子机制。